Neurocrine Biosciences Inc vs Vanguard Information Technology Index Fund ETF — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Vanguard Information Technology Index Fund ETF trades at $115.88. The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, Vanguard Information Technology Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| NBIX | VGT | |
|---|---|---|
Market Cap | $17.40B | — |
Sector | Health | — |
52-Week High | $180.55 | $125.77 |
52-Week Low | $123.10 | $83.59 |
Enterprise Value | $16.49B | — |
Trailing returns across standard periods
Latest headlines on both assets
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VGT →